Autolus Therapeutics shares are trading higher after the company announced the presentation of top-line data from the Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-cell Acute Lymphoblastic Leukemia at ASCO.
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics announced top-line data from the Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-cell Acute Lymphoblastic Leukemia, leading to a rise in its share price.
June 02, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Autolus Therapeutics shares are trading higher after the company announced positive top-line data from the Phase 2 FELIX study of obe-cel in adult r/r B-cell Acute Lymphoblastic Leukemia.
The positive top-line data from the Phase 2 FELIX study of obe-cel in adult r/r B-cell Acute Lymphoblastic Leukemia indicates that the company's product is showing promising results. This news is likely to boost investor confidence in Autolus Therapeutics, leading to a short-term increase in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100